Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Regulatory Officer | September 11, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,289 |
Ending reported balance
After 2026-09-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-11 · Grant · Acquired 4,483 · Balance 20,708 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. Row 2 · 2026-09-11 · Tax withholding · Disposed 2,419 · Balance 18,289 F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2024 Filed Mar 1, 2024 00:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,544 | $136.00 | $209,984.00 |
DisclosureSEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · nonDerivative · entry 6 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,507 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 00:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,544 | $79.02 | $122,006.88 |
DisclosureSEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · nonDerivative · entry 5 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 00:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,500 | $134.62 | $336,550.00 |
DisclosureSEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · nonDerivative · entry 4 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,507 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $133.87 to $135.86. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 00:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,500 | $79.02 | $197,550.00 |
DisclosureSEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · nonDerivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 00:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,500 | $135.64 | $339,103.50 |
DisclosureSEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,507 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $135.27 to $136.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 00:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,500 | $79.02 | $197,550.00 |
DisclosureSEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 5,604 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000071 · wk-form4_1708036687.xml · derivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,604 Underlying: Common Stock · 5,604 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 28,161 | $0.00 Strike: $133.84 | $0.00 |
DisclosureSEC source: 0000914475-24-000071 · wk-form4_1708036687.xml · derivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,161 Underlying: Common Stock · 28,161 shares Expires 2034-02-13 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 716 | $133.03 | $95,252.77 |
DisclosureSEC source: 0000914475-24-000071 · wk-form4_1708036687.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,507 F1 · kind: Sale of 716 shares of common stock issued upon vesting of 1,358 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (642) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.52. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 01, 2024 Filed Feb 3, 2024 00:14 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 623 | $139.77 | $87,076.71 |
DisclosureSEC source: 0000914475-24-000026 · wk-form4_1706919254.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,865 F2 · kind: Sale of 623 shares of common stock issued upon vesting of 1,179 restricted stock units on February 1, 2024 to cover payroll and withholding taxes, with the balance of the shares (556) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:14 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 422 | $141.94 | $59,898.68 |
DisclosureSEC source: 0000914475-24-000026 · wk-form4_1706919254.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,309 F1 · kind: Sale of 422 shares of common stock issued upon vesting of 800 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (378) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 20:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,431 | $107.52 | $153,861.12 |
DisclosureSEC source: 0001209191-23-047747 · doc4.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,931 F1 · kind: Sale of 1,431 shares of common stock issued upon vesting of 2,717 restricted stock units on August 28, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,286) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F1 · shares: Sale of 1,431 shares of common stock issued upon vesting of 2,717 restricted stock units on August 28, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,286) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| August 21, 2023 Filed Aug 24, 2023 00:04 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,404 | $107.42 | $150,820.35 |
DisclosureSEC source: 0001209191-23-047134 · doc4.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,645 F1 · kind: Sale of 1,404 shares of common stock issued upon vesting of 2,667 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,263) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.99 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:32 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 5,434 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009901 · doc4.xml · derivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,434 Underlying: Common Stock · 5,434 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:32 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 33,771 | $0.00 Strike: $103.52 | $0.00 |
DisclosureSEC source: 0001209191-23-009901 · doc4.xml · derivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,771 Underlying: Common Stock · 33,771 shares Expires 2033-02-13 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.